JB Pharma Q4 net profit up 43% to Rs 126 crore

At the operating level, EBITDA rose to Rs 197.7 crore in the third quarter of this fiscal over Rs 163 crore YoY. EBITDA margins came in at 23 percent against 21.4 percent (YoY).

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Indian drug major JB Chemicals & Pharmaceuticals Ltd on May 17 reported a 43 percent jump in net profit at Rs 126.2 crore for the January-March quarter of FY24, from Rs 88 crore a year ago.

Revenue from operations came in at Rs 861.7 crore, up 13 percent from Rs 762 crore in the year-ago quarter.

At the operating level, EBITDA rose to Rs 197.7 crore in the third quarter of this fiscal over Rs 163 crore YoY. EBITDA margins came in at 23 percent against  21.4 percent (YoY).

"With continued thrust on Domestic and CDMO businesses, we feel confident that the company will continue to deliver sustained revenue growth and improved operating margins in the medium to long term," said Nikhil Chopra, CEO & Whole Time Director in a press statement.

Domestic business revenue grew 22 percent to Rs 465 crores. Excluding recently added ophthalmology portfolio, organic growth for domestic business was 13 percent. Acute season remained weak throughout the year and impacted overall growth.

International business revenue grew 4 percent to Rs 397 crores. For the first time ever in any fourth quarter, CDMO business crossed INR 100 crores revenue.

Other Expenses increased to R s211 crores vs Rs 188 crores YoY primarily due to high freight costs on account of the international business Q4 FY24 126 Q4 FY24. Depreciation increased to Rs 41 crores as compared to Rs 32 crores primarily on account of amortization of the ophthalmology distribution and promotion license fees. Finance cost reduced to Rs 9 crores vs Rs 14 crores YoY on account of debt repayment during the quarter.

Gross debt reduced to Rs 357 crores as on 31st Mar 2024 from Rs 548 crores as on 31st Mar 2023. Net Capex additions for the year was Rs 135 crores chiefly on account of expansion of the lozenges manufacturing facility in Daman.

 JB Chemicals & Pharmaceuticals Ltd was originally set up as JB Mody Chemicals and Pharmaceuticals Ltd, by the promoter, JB Mody and his family in 1976, to manufacture APIs and formulations. The company was renamed in 1985. The manufacturing units are in Ankleshwar and Panoli (both in Gujarat), and Daman (Union Territory of Daman and Diu). The company manufactures a wide range of pharmaceutical formulation specialties, radio-diagnostics, APIs and intermediates.